The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Inhibition of Galectins with Small Molecules

På svenska

Author

Summary, in English

Evidence that the galectin family of proteins plays crucial roles in cancer, inflammation, and immunity has accumulated over the last decade. The galectins have consequently emerged as interesting drug targets. A majority of galectin functions occurs by means of cross-linking glycoproteins and by doing so controlling gly-coproteirl cellular localization and residence times. The glycoprotein cross-linking occurs when galectin dimers or multimers, or galectins with two binding sites, bind galactose-containing glycans of the glycoproteins. Such galectin-glycan interactions have been successfully blocked with compounds having multivalent presentation of galactose, lactose, or N-acetyllactosamine, with peptides, and with small carbohydrate (galactose) derivatives. This review summarizes and analyzes attempts to develop efficient and selective small-molecule galectin inhibitors through derivatization of monosaccharides, mainly galactosides, with non-carbohydrate structures that protrude into subsites adjacent to the core-conserved galactose-recognizing site of the galectins.

Department/s

Publishing year

2011

Language

English

Pages

18-23

Publication/Series

Chimia

Volume

65

Issue

1-2

Document type

Journal article

Publisher

Swiss Chemical Society

Topic

  • Microbiology in the medical area
  • Immunology in the medical area

Keywords

  • Cancer
  • Galectin
  • Immunity
  • Inflammation
  • Inhibitor

Status

Published

ISBN/ISSN/Other

  • ISSN: 0009-4293